These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1299977)

  • 1. [Adverse effects of oxybutynin chloride (Ditropan). Evaluation of the official survey of Regional Pharmacovigilance Centers].
    Jonville AP; Dutertre JP; Autret E; Barbellion M
    Therapie; 1992; 47(5):389-92. PubMed ID: 1299977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adverse effects of oxybutynin chloride (Ditropan) in pediatrics].
    Jonville AP; Dutertre JP; Barbellion M; Autret E
    Arch Fr Pediatr; 1993 Jan; 50(1):27-9. PubMed ID: 8507135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.
    Gish P; Mosholder AD; Truffa M; Johann-Liang R
    J Pediatr; 2009 Sep; 155(3):432-4. PubMed ID: 19732583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neuropsychiatric adverse effects attributed to use of oxybutynin].
    t'Veld BA; Kwee-Zuiderwijk WJ; van Puijenbroek EP; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(11):590-2. PubMed ID: 9623118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxybutynin efficacy in the treatment of primary enuresis.
    Lovering JS; Tallett SE; McKendry JB
    Pediatrics; 1988 Jul; 82(1):104-6. PubMed ID: 3288951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder].
    Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T
    Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
    Von Zweigbergk M; Nordin B; Jonsson S
    Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
    [No Abstract]   [Full Text] [Related]  

  • 9. [Role of adverse effects of immuno-allergic nature at a Regional Pharmacovigilance Center].
    Sorbette F; Conte S; Montastruc JL
    Therapie; 1992; 47(5):445-6. PubMed ID: 1299998
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.
    Van Arendonk KJ; Knudson MJ; Austin JC; Cooper CS
    Urology; 2006 Oct; 68(4):862-5. PubMed ID: 17070368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of unexpected and toxic effects of omeprazole (Mopral) reported to the regional centers of pharmacovigilance during the first 22 postmarketing months].
    Castot A; Bidault I; Dahan R; Efthymiou ML
    Therapie; 1993; 48(5):469-74. PubMed ID: 8146827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective study of adverse drug reactions in the elderly: experience of regional center for pharmacovigilance].
    Bruneau S; Bruhat C; Lagarce L; Lainé-Cessac P
    Therapie; 2001; 56(6):785-91. PubMed ID: 11878111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Overdose of anticholinergic agents and confusional syndrome].
    Choulot JJ; Mensire A; Saint Martin J
    Ann Pediatr (Paris); 1989 Dec; 36(10):714. PubMed ID: 2624388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers.
    Shin YS; Lee YW; Choi YH; Park B; Jee YK; Choi SK; Kim EG; Park JW; Hong CS
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):910-5. PubMed ID: 19621345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Instability of the detrusor. Treatment with oxybutynin chloride (Ditropan) in children].
    Vallejo Herrador J; Rodríguez Luna JM; Fernández Fernández A; Perales Cabanas L; Romero Maroto J; Pérez Bustamante I
    Actas Urol Esp; 1990; 14(1):23-7. PubMed ID: 2339646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing an adverse drug reaction reporting system at a teaching hospital.
    Baniasadi S; Fahimi F; Shalviri G
    Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):408-11. PubMed ID: 18312492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
    Palmer LS; Zebold K; Firlit CF; Kaplan WE
    J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.